Molecular analysis of cell survival and death pathways in the proteasome inhibitor bortezomib-resistant PC3 prostate cancer cell line.

Kanbur E., Baykal A. T., Yerlikaya A.

Medical oncology (Northwood, London, England), vol.38, pp.112, 2021 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 38
  • Publication Date: 2021
  • Doi Number: 10.1007/s12032-021-01563-1
  • Journal Name: Medical oncology (Northwood, London, England)
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, BIOSIS, CINAHL, EMBASE, MEDLINE
  • Page Numbers: pp.112
  • Keywords: Bortezomib, Prostate, Cancer, ERK, LC3, CDK2, MELK
  • Kütahya Health Sciences University Affiliated: Yes